Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice

  • Isidro‑Hernández, Marta
  • Casado-García, Ana
  • Oak, Ninad
  • Alemán-Arteaga, Silvia
  • Ruiz-Corzo, Belén
  • Martínez-Cano, Jorge
  • Mayado, Andrea
  • Sánchez, Elena G.
  • Blanco, Óscar
  • Gaspar, Ma Luisa
  • Orfao, Alberto
  • Alonso-López, Diego
  • De Las Rivas, Javier
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • González-Murillo, África
  • Criado, Francisco Javier García
  • García-Cenador, Begoña
  • Ramírez-Orellana, Manuel
  • de Andrés, Belén
  • Vicente-Dueñas, Carolina
  • Cobaleda, César
  • Nichols, Kim E.
  • Sánchez García, Isidro
The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5 B-cell precursors toward leukemia. Transcriptional profiling reveals that Myd88 is downregulated in immune-stressed pre-malignant B-cell precursors and in leukemic cells. Genetic reduction of Myd88 expression leads to a significant increase in leukemia incidence in Pax5 Myd88 mice through an inflammation-dependent mechanism. Early induction of Myd88-independent Toll-like receptor 3 signaling results in a significant delay of leukemia development in Pax5 mice. Altogether, these findings identify a role for innate immunity dysregulation in leukemia, with important implications for understanding and therapeutic targeting of the preleukemic state in children., Research at C. Cobaleda’s laboratory was partially supported by Ministerio de Ciencia e Innovación/AEI/FEDER (PID2021-122787OBI00), and a Research Contract with the “Fundación Síndrome de WolfHirschhorn o 4p-”. Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. Research in C. Vicente-Dueñas group has been funded by Instituto de Salud Carlos III through the project “ PI22/00379 and by a “Miguel Servet Grant” [CPII19/00024-AES 2017-2020; co-funded by European Regional Development Fund (ERDF)/European Social Fund (ESF) “A way to make Europe”/“Investing in your future”]. Kim Nichols receives funding from the American Lebanese Syrian Associated Charities (ALSAC) and R01CA241452 from the National Cancer Institute Research in ISG group is partially supported by FEDER and by SAF2015-64420-R MINECO/FEDER, UE; by RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE; by PID2021-122185OB-I00 MCIU/AEI/FEDER, UE, and by Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18, and CSI144P20). Research in BdA group is partially supported by RTI2019- 09114-B-I00 MCIU/AEI/FEDER, UE. M. Ramírez-Orellana and I. Sánchez-García have been supported by the Fundacion Unoentrecienmil (CUNINA project). C. Cobaleda, M. Ramírez-Orellana, and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC). A. Casado-García (CSI067-18) and M. Isidro-Hernández (CSI021-19) are supported by FSE-Conserjería de Educación de la Junta de Castilla y León 2019 and 2020 (ESF, European Social Fund) fellowship, respectively. S. Alemán-Arteaga is supported by an Ayuda para Contratos predoctorales para la formación de doctores (PRE2019- 088887). J. Martínez-Cano is supported by a predoctoral fellowship FPI-UAM 2019. We also thank the Hartwell Center and Dr. Ti-Cheng Chang from the Center for Bioinformatics at SJCRH for their support of the whole genome sequencing and bioinformatic pipelines., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Proof-of-principle: targeted childhood leukemia prevention

  • Cobaleda, César
  • Ramírez-Orellana, Manuel
  • Vicente-Dueñas, Carolina
  • Weiss, Andreas
  • Nichols, Kim E.
  • Sánchez-García, Isidro
Cancer is the most common cause of disease-related childhood mortality in developed countries, with B-cell acute lymphoblastic leukemia (B-ALL) representing the most frequent. A salient characteristic underlying some cases of childhood B-ALL is the presence of congenital mutations (either inherited or de novo) that are compatible with normal lymphocyte development, but lead to the appearance of a silent population of preleukemic cells that acquire additional genetic mutations and ultimately progress to full-blown B-ALL. The precise mechanisms underlying malignant transformation have been difficult to ascertain due to their development in otherwise healthy-appearing children. Notably, several decades ago, delayed exposure to common infections was postulated as a triggering factor leading to the appearance of the secondary genetic lesions required for B-ALL to develop [1]., Research at C. Cobaleda’s laboratory was partially supported by Ministerio de Ciencia e Innovación/AEI/FEDER (PID2021-122787OB-I00), and a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-”. Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. Research in C. Vicente-Dueñas group has been funded by Instituto de Salud Carlos III through the project “PI22/00379 and by a “Miguel Servet Grant” [CPII19/00024 - AES 2017-2020; co-funded by European Regional Development Fund (ERDF)/European Social Fund (ESF) “A way to make Europe”/”Investing in your future”]. Kim Nichols receives funding from the American Lebanese Syrian Associated Charities (ALSAC) and R01CA241452 from the National Cancer Institute Research in ISG group is partially supported by FEDER and by RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE; by PID2021-122185OB-I00 MCIU/AEI/FEDER, UE, and by Junta de Castilla y León (UIC-017, and CSI144P20). M. Ramírez-Orellana and I. Sánchez-García have been supported by the Fundacion Unoentrecienmil (CUNINA project). C. Cobaleda, M. Ramírez-Orellana, and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Childhood B cell leukemia: Intercepting the paths to progression

  • Cobaleda, Cesar
  • Vicente-Dueñas, Carolina
  • Nichols, Kim E.
  • Sánchez García, Isidro
B-cell Acute Lymphoblastic Leukemia (B-ALL) is the most common pediatric cancer, arising most often in children aged 2–5 years. This distinctive age distribution hints at an association between B-ALL development and disrupted immune system function during a susceptible period during childhood, possibly triggered by early exposure to infection. While cure rates for childhood B-ALL surpass 90% in high-income nations, survivors suffer from diminished quality of life due to the side effects of treatment. Consequently, understanding the origins and evolution of B-ALL, and how to prevent this prevalent childhood cancer, is paramount to alleviate this substantial health burden. This article provides an overview of our current understanding of the etiology of childhood B-ALL and explores how this knowledge can inform preventive strategies., PID2021-122787OB-I00/Ministerio de Ciencia e Innovación/AEI/FEDER Fundación Ramón Areces Banco de Santander PI22/00379/Instituto de Salud Carlos III (ISCIII)/ FEDER European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF))
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Deletion of 9p drives B-ALL through heterozygous inactivation of Pax5 and Cd72 in preleukemic cells

  • Ruiz-Corzo, Belén
  • Casado-García, Ana
  • Oak, Ninad
  • Somoza-Cotillas, Paula
  • López-Álvarez de Neyra, Andrea
  • Martínez-Cano, Jorge
  • Pérez-Pons, Alba
  • Sánchez, Elena G.
  • Blanco, Oscar
  • Blanco, Oscar
  • Alonso-López, Diego
  • De Las Rivas, Javier
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • García Criado, Francisco Javier
  • García Cenador, María Begoña
  • Orfao, Alberto
  • Ramírez-Orellana, Manuel
  • Cobaleda, César
  • Vicente-Dueñas, Carolina
  • Nichols, Kim E.
  • Sánchez-García, Isidro
The contribution of 9p deletion to B cell acute lymphoblastic leukemia (B-ALL) has remained elusive since its discovery more than 40 years ago. Here we show that loss of CD72 is recurrent in B-ALL cases containing PAX5 deletions, and that Cd72 haploinsufficiency drives B-ALL development in Pax5+/- mice. Mechanistically, Cd72+/-;Pax5+/- precursor B cells exhibited an inflammatory transcriptional profile characterized by a decrease in Myd88 expression, a finding that aligns with our previous studies of B-ALL development in Pax5+/- mice following exposure to immune stressors. These combined genomic analyses and functional models provide compelling evidence that co-deletion of 2 contiguous genes, Pax5 and Cd72, drives B cell leukemogenesis., MICIU/AEI/ 10.13039/501100011033 and ERDF/EU grants PID2021-122185OB-I00 and PID2024-155590OB-I00 (to ISG). Junta de Castilla y León grants UIC-017, CSI144P20, and CSI016P23 (to ISG). Fundacion Unoentrecienmil CUNINA2 project (to ISG). Fundación Científica de la Asociación Española contra el Cáncer (TRNSC247893SÁNC) (to ISG). Instituto de Salud Carlos III (ISCIII) (AC24/00021) (to ISG). Fundación Científica de la Asociación Española contra el Cáncer grant PRYCO211305SANC (to CC, MR, and ISG). “La Caixa” Foundation under the project code LCF/PR/HR25/52450048 (to CC, MR, and ISG). TRANSCAN2023-1858-066 – REACTION Project (to MR and ISG). Research at C. Cobaleda’s laboratory was partially supported by Grant PID2021-122787OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and ERDF/EU grant PID2021-122787OB-I00 (to CC). “Fundación Síndrome de Wolf-Hirschhorn o 4p-” research contract (to CC). “Fundación Ramón Areces” and “Banco de Santander” institutional grants to the Centro de Biología Molecular. Instituto de Salud Carlos III (ISCIII) project PI22/00379 (to CVD). American Lebanese Syrian Associated Charities (ALSAC) (to KEN). National Cancer Institute/NIH grant R01CA241452 (to KEN). National Institute of Allergy and Infectious Diseases Histiocytosis Association Cures within Reach grant R21AI113490 (to KEN). Asociación Pablo Ugarte (to MR). FSE-Conserjería de Educación de la Junta de Castilla y León 2019 (ESF, European Social Fund) fellowship CSI067-18 (to ACG). Juan de la Cierva 2022 grant JDC2022-049078-I (to ACG). FSE-Conserjería de Educación de la Junta de Castilla y León 2022 (ESF, European Social Fund) fellowship CSI002-22 (to BRC). Ayuda para Contratos predoctorales para la formación de doctores (PRE2022-103628) (to ALAN). Universidad Autónoma de Madrid predoctoral fellowship FPI-UAM 2019 (to JMC).